NEWTOWN, PENNSYLVANIA AND VANCOUVER, BRITISH COLUMBIA – Helius Medical Technologies, Inc. (CSE: HSM) (“Helius” or the “Company”) is pleased to announce that it has retained Brian Bapty, Ph.D., as a consultant.
Dr. Bapty received his Ph.D. in Experimental Medicine and his B.Sc. in Cell and Developmental Biology from the University of British Columbia. His extensive experience in capital markets and prior work with institutional investors will be invaluable as the Company continues to attract investor interest and build shareholder value with the development of its patent pending technology that is believed will enable the first non-invasive means for delivering neurostimulation through the oral cavity (the “PoNS™“).
The Company will grant stock options to Dr. Bapty to purchase up to 100,000 common shares at a price of CAD $2.52 per share, exercisable until July 14, 2017, with one-quarter of such stock options vesting on the date of grant and the remaining three-quarters vesting quarterly on September 30 and December 31 2014, and March 31, 2015.
For further information, please contact:
Phil Deschamps, President, CEO and Director, at 267-756-7028, ext. 1061
CAUTIONARY DISCLAIMER STATEMENT: The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.